Twist Bioscience CEO sells 18,880 shares
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an open-market sale of 18,880 shares of common stock at $95.00 per share on June 25, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an open-market sale of 18,880 shares of common stock at $95.00 per share on June 25, 2026. After this sale, she directly holds 824,039 common shares. The filing also lists outstanding employee stock options, including 16,470 options exercisable at $8.82 expiring in 2027 and 64,950 options at $67.85 expiring in 2030. The transactions were made under a pre-established Rule 10b5-1 trading plan.
Insider Trade Summary 10b5-1
Net Seller: 18,880 shares
Net Sell
6 txns
Insider
Leproust Emily M.
Role
Chief Executive Officer
Sold
18,880 shs ($1.79M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 18,880 | $95.00 | $1.79M |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Common Stock — 824,039 shares (Direct);
Employee Stock Option (right to buy) — 81,420 contracts (Direct)
Footnotes (6)
- F1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025.
- F2. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F3. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F4. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F5. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
- F6. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
Key Figures
Shares sold: 18,880 shares
Sale price: $95.00 per share
Shares held after sale: 824,039 shares
+4 more
7 metrics
Shares sold
18,880 shares
Common stock sale on June 25, 2026
Sale price
$95.00 per share
Common stock open-market sale
Shares held after sale
824,039 shares
Post-transaction direct common stock holdings
Option strike price
$8.82 per share
Employee stock option, expires September 28, 2027
Underlying shares at $8.82
16,470 shares
Common stock underlying employee stock option
Option strike price
$67.85 per share
Employee stock option, expires August 31, 2030
Underlying shares at $67.85
64,950 shares
Common stock underlying employee stock option
Key Terms
Rule 10b5-1 trading plan, Employee Stock Option (right to buy), performance stock options, Common Stock, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Employee Stock Option (right to buy) financial
"security_title": "Employee Stock Option (right to buy)""
performance stock options financial
"Represents performance stock options granted to the reporting person on September 1, 2020..."
Common Stock financial
"underlying_security_title": "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
vesting financial
"1/48th of the shares subject to the option vest on each monthly anniversary thereafter..."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Twist Bioscience (TWST) report for its CEO?
Twist Bioscience CEO Emily M. Leproust reported selling 18,880 shares of common stock. The sale occurred on June 25, 2026 at a reported price of $95.00 per share, according to the Form 4 insider trading disclosure.
Was the Twist Bioscience (TWST) CEO sale made under a Rule 10b5-1 plan?
Yes. The Form 4 states the transactions were effected pursuant to a Rule 10b5-1 trading plan. That plan was previously adopted by the reporting person on May 27, 2025, indicating the sales were pre-arranged rather than newly decided.
What stock options does the Twist Bioscience (TWST) CEO still hold?
The filing shows the CEO holds employee stock options over 16,470 underlying shares at an $8.82 exercise price expiring in 2027 and 64,950 underlying shares at a $67.85 exercise price expiring in 2030, all tied to Twist Bioscience common stock.
Does the Form 4 show any option exercises for Twist Bioscience (TWST)?
The summary data indicate no derivative exercises during this reporting period. Instead, the Form 4 mainly lists existing employee stock option positions alongside the CEO’s sale of 18,880 shares of Twist Bioscience common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates